Affinage

F10

Coagulation factor X · UniProt P00742

Length
488 aa
Mass
54.7 kDa
Annotated
2026-06-14
39 papers in source corpus 20 papers cited in narrative 20 extracted findings
Cross-family judge vs UniProt: tie

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

Coagulation factor X (F10) is a vitamin K-dependent serine protease zymogen synthesized as a single-chain precursor with a prepro leader and processed to a dimeric form, with a coding sequence homologous to factor IX and prothrombin consistent with origin by gene duplication (PMID:3011603); it is essential for hemostasis, as its loss in mice causes partial embryonic lethality and fatal neonatal intraabdominal hemorrhage (PMID:10739370). Membrane engagement is mediated by its Gla domain, which binds a single phosphatidylserine molecule per domain while remaining membrane contacts are satisfied by phosphatidylethanolamine (PMID:34894064). Beyond clotting, the activated protease FXa functions as a signaling molecule: it drives mesangial cell mitogenesis through a protease-activated receptor with calcium mobilization, JNK/tyrosine kinase activation and PDGF induction (PMID:11316847), promotes retinal pigment epithelial epithelial-mesenchymal transition and fibrosis via PAR1/p38 MAPK (PMID:34283209), and in tumors promotes androgen-independent prostate growth through PAR2/ERK1/2 signaling (PMID:39303726). Extravascular F10 produced by myeloid cells—monocytes, macrophages, and PMN-MDSCs whose expression is enhanced by CD84 ligation—reprograms tumor-associated macrophages through PAR2 to drive immune evasion (PMID:31541031, PMID:39303726). F10 is regulated transcriptionally by a TATA-less promoter bound by NF-Y, HNF-4 and GATA-4 (PMID:11154110), and its carboxyl-terminal region downstream of K467 is dispensable for secretion and procoagulant activity, unlike the homologous regions of related zymogens (PMID:26083275). F10 is also a key host factor exploited by adenovirus type 5, which binds the viral hexon protein to shield the virus from IgM/classical-complement neutralization and to bridge it to heparan sulfate proteoglycans for liver transduction (PMID:23524342, PMID:20949078). Several pathogen proteases target FX directly: Porphyromonas gingivalis gingipain-R cysteine proteinases activate it (PMID:9188512), whereas the Capnocytophaga canimorsus dipeptidyl peptidase CcDPP7 inactivates it by N-terminal cleavage, prolonging clotting in vivo (PMID:28029716).

Mechanistic history

Synthesis pass · year-by-year structured walk · 20 steps
  1. 1986 Medium

    Establishing the primary structure showed FX is a single-chain precursor processed to a dimeric protease and revealed its evolutionary relationship to factor IX and prothrombin.

    Evidence cDNA cloning and sequencing from a human liver library

    PMID:3011603

    Open questions at the time
    • Does not define functional domain boundaries
    • No experimental processing kinetics
  2. 1997 High

    Demonstrated that a bacterial cysteine proteinase can directly activate FX, broadening activators beyond the physiological tenase complexes.

    Evidence In vitro enzyme kinetics and clotting assays with P. gingivalis gingipain-Rs and purified FX

    PMID:9188512

    Open questions at the time
    • In vivo relevance to periodontal coagulopathy not established
    • Cleavage site not mapped here
  3. 1998 Medium

    Mapped a snake venom protein's binding to the FX Gla domain, identifying residues 1-44 and the Gla C-terminus as critical for folding and binding.

    Evidence Protein sequencing, Gla-peptide solid-phase binding inhibition, Ca2+ binding measurements, 3D modeling

    PMID:9860851

    Open questions at the time
    • No co-crystal structure
    • Physiological consequence of Gla-domain sequestration in vivo not addressed
  4. 2000 High

    Genetic knockout established FX as non-redundantly essential for both embryonic and postnatal hemostasis.

    Evidence Targeted gene replacement knockout mice with developmental phenotyping

    PMID:10739370

    Open questions at the time
    • Cause of partial embryonic lethality versus neonatal bleeding not molecularly dissected
    • No conditional/tissue-specific resolution
  5. 2000 Medium

    Defined the transcriptional control of F10, identifying NF-Y as the dominant activator of the TATA-less promoter.

    Evidence DNase I footprinting, EMSA, and reporter assays in HepG2 cells

    PMID:11154110

    Open questions at the time
    • Mapped in murine promoter/hepatic context only
    • Does not address extravascular/myeloid expression control
  6. 2001 Medium

    Showed FXa is a mitogen acting through a protease-activated receptor (not EPR-1), establishing a non-hemostatic signaling role in proliferative kidney disease.

    Evidence DNA synthesis, signaling inhibitor panel, and RT-PCR in cultured human mesangial cells

    PMID:11316847

    Open questions at the time
    • Specific PAR subtype not identified
    • In vivo glomerular relevance not tested
  7. 2010 High

    Defined the mechanism of FX-mediated adenovirus liver targeting, showing the Ad5:FX complex bridges to heparan sulfate proteoglycans with integrin requirement for internalization.

    Evidence Enzymatic HS removal, sulfated-heparin competition, integrin-mutant vectors, in vivo liver assays

    PMID:20949078

    Open questions at the time
    • Hexon binding interface not structurally resolved here
    • Quantitative contribution of distinct HSPGs unresolved
  8. 2011 Medium

    Demonstrated that the Ad5-FX-HSPG liver-targeting pathway is conserved in non-human primates, supporting translational relevance.

    Evidence Quantitative biodistribution of wild-type vs FX-binding-ablated Ad5 in Microcebus murinus

    PMID:21677690

    Open questions at the time
    • Single species/single lab
    • Does not address human in vivo behavior
  9. 2012 High

    Established that virus-bound FX, when mislocalized into macrophages, triggers a defined TLR4/MyD88/TRIF/TRAF6/NF-κB innate immune program.

    Evidence Interaction-ablating mutagenesis with genome-wide transcriptional profiling in vivo

    PMID:23019612

    Open questions at the time
    • Intracellular FX sensor not identified
    • Does not address whether endogenous FX triggers similar sensing
  10. 2013 High

    Resolved the protective function of FX binding, showing it shields adenovirus from IgM and classical-complement neutralization to enable liver transduction.

    Evidence Serum neutralization assays with FX blocking and in vivo transduction in antibody-, C1q-, and C4-deficient mice

    PMID:23524342

    Open questions at the time
    • Does not extend to alternative complement pathway
    • Human serum context not fully resolved
  11. 2015 Medium

    Showed the FX C-terminal region (downstream of K467) is dispensable for secretion and activity, distinguishing FX from homologous zymogens.

    Evidence Truncated and chimeric recombinant FX variants across multiple cell lines with functional assays

    PMID:26083275

    Open questions at the time
    • Functional role of the C-terminus, if any, undefined
    • No in vivo correlate
  12. 2017 Low

    Identified the structural basis of PS-specific membrane recognition by the FX Gla domain through simulation.

    Evidence Molecular dynamics simulations with highly mobile membrane mimetic

    PMID:28782177

    Open questions at the time
    • Computational only, no mutagenesis or biophysical validation of the identified sites
    • Predicted binding residues not experimentally confirmed
  13. 2017 High

    Demonstrated a bacterial protease that inactivates FX, defining a mechanism of pathogen-induced anticoagulation.

    Evidence Gene mutagenesis, purified CcDPP7 biochemistry, N-terminal sequencing, and in vivo bleeding time

    PMID:28029716

    Open questions at the time
    • Clinical relevance in C. canimorsus infection not established
    • Effect on FX signaling functions untested
  14. 2018 Low

    Proposed that FX recruits and M2-polarizes macrophages in glioblastoma via direct ERK1/2 binding under miRNA/lncRNA control.

    Evidence Chemotaxis, polarization, co-IP for ERK1/2, phosphorylation blots, miRNA modulation

    PMID:30034397

    Open questions at the time
    • FX-ERK1/2 interaction lacks rigorous specificity controls
    • Direct binding versus indirect signaling not distinguished
  15. 2019 High

    Established myeloid cells as a critical extravascular FX source and FXa-PAR2 signaling as a driver of tumor immune evasion.

    Evidence Myeloid-specific conditional FX knockout plus rivaroxaban across multiple mouse cancer models

    PMID:31541031

    Open questions at the time
    • Receptor downstream effectors in macrophages incompletely mapped
    • Human tumor translation not established
  16. 2021 Medium

    Quantified single-site PS specificity of the Gla domain, refining the membrane-binding model.

    Evidence Surface plasmon resonance with defined-composition Nanodiscs

    PMID:34894064

    Open questions at the time
    • Structural identity of the single PS site not directly mapped
    • Implications for tenase/prothrombinase assembly not tested
  17. 2021 Medium

    Extended FXa signaling to ocular fibrosis through a PAR1/p38 MAPK and TGF-β-cooperative pathway.

    Evidence RPE EMT assays, in vivo PVR model, and inhibitor panels for FXa/thrombin/TGF-βR

    PMID:34283209

    Open questions at the time
    • Relative contribution of PAR1 vs TGF-βR not quantified
    • Source of intraocular FX not defined
  18. 2024 High

    Defined PMN-MDSCs as an extrahepatic FX source driving prostate cancer growth via PAR2/ERK1/2, with CD84 ligation enhancing F10 expression.

    Evidence scRNA-seq, genetic/pharmacological FXa inhibition, ERK1/2 assays, CD84 ligation in mouse CRPC models

    PMID:39303726

    Open questions at the time
    • Mechanism linking CD84 to F10 transcription unresolved
    • Human CRPC validation limited
  19. 2024 Medium

    Identified an FXa residue (F174) governing direct-inhibitor and TFPI sensitivity, informing engineered variants that bypass anticoagulants.

    Evidence Site-directed mutagenesis, thrombin generation in patient plasma, and MD simulation

    PMID:38729577

    Open questions at the time
    • In vivo efficacy and safety untested
    • Structural mechanism of altered TFPI binding not resolved
  20. 2025 Medium

    Showed glioblastoma cells autonomously express and secrete catalytically active FX, including a C-terminal-truncated splice form, inducible by inflammatory and metabolic stress.

    Evidence Isoform sequencing, chromogenic activity, and thrombin generation on conditioned medium

    PMID:40149552

    Open questions at the time
    • Functional role of the truncated isoform unclear
    • Link to tumor coagulopathy in patients not established

Open questions

Synthesis pass · forward-looking unresolved questions
  • How extravascular/tumor-derived FX is activated, which PAR subtype dominates in each tissue context, and the structural basis of FX-mediated host signaling versus hemostatic activation remain unresolved.
  • No unified structural model linking Gla-domain membrane binding to PAR signaling
  • Tissue-specific FX activator(s) in tumors unidentified
  • Mechanism connecting myeloid F10 expression control to immune evasion incomplete

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060089 molecular transducer activity 4 GO:0140096 catalytic activity, acting on a protein 4 GO:0008289 lipid binding 2 GO:0016787 hydrolase activity 2
Localization
GO:0005576 extracellular region 3
Pathway
R-HSA-168256 Immune System 4 R-HSA-162582 Signal Transduction 3 R-HSA-1643685 Disease 3 R-HSA-109582 Hemostasis 2
Partners
ERK1ERK2PAR1PAR2

Evidence

Reading pass · 20 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2019 Myeloid cell-derived FXa promotes tumor immune evasion by signaling through protease-activated receptor 2 (PAR2), reprogramming tumor-associated macrophages; monocytes and macrophages were identified as crucial extravascular sources of FX in the tumor microenvironment. Conditional knockout mice lacking myeloid cell FX production; pharmacological inhibition with rivaroxaban; mechanistic signaling studies in tumor models Science immunology High 31541031
2013 FX binding to Ad5 hexon protein protects adenovirus from neutralization by natural IgM and the classical complement pathway, enabling liver transduction; FX was not required for liver transduction in mice lacking antibodies, C1q, or C4. In vitro serum neutralization assays with FX-blocking; in vivo liver transduction in antibody-deficient, C1q-deficient, and C4-deficient mice Nature medicine High 23524342
2012 The HAdv-FX complex activates a distinct NF-κB-dependent innate immune gene network downstream of TLR4/MyD88/TRIF/TRAF6 signaling; misplacement of FX from blood into intracellular macrophage compartments upon virus entry triggers this innate immune response. Structure-guided mutagenesis to ablate HAdv-FX complex formation; in vivo genome-wide transcriptional profiling comparing wild-type vs. FX-binding-ablated virus Science (New York, N.Y.) High 23019612
2010 Ad5 binds FX via the hexon protein; the Ad5:FX complex targets heparan sulfate proteoglycans (HSPGs) on cell surfaces, with O-linked sulfate groups critical for binding; integrin αv engagement is required for efficient post-attachment internalization. Enzymatic removal of HS side chains; competition with sulfated heparins; in vivo liver accumulation assays; Ad5 vectors with CAR- and αv-integrin binding mutations PLoS pathogens High 20949078
2024 FXa promotes androgen-independent prostate tumor growth by activating PAR2 and phosphorylation of ERK1/2 in tumor cells; immunosuppressive PMN-MDSCs are a key extrahepatic source of FX in the prostate TME; CD84 ligation on PMN-MDSCs enhances F10 expression. scRNA-seq; genetic and pharmacological inhibition of FXa; ERK1/2 phosphorylation assays; CD84 ligation experiments in mouse CRPC models Cancer cell High 39303726
1997 Arginine-specific cysteine proteinases (gingipain-Rs) from Porphyromonas gingivalis directly activate human factor X in a dose- and time-dependent manner with Km below normal plasma FX concentration; the 95-kDa form is 5-fold more efficient than the 50-kDa form and is potentiated by phospholipids. In vitro enzyme kinetics assays; clotting time assays in factor-deficient plasmas; reconstitution with purified FX The Journal of biological chemistry High 9188512
1998 X-bp from Deinagkistrodon acutus venom is a heterodimeric C-type lectin-like protein that binds the Gla domain of factor X (residues 1-44); the C-terminal region of the Gla domain peptide is critical for correct folding and binding; X-bp binds two Ca2+ ions per molecule. Protein isolation; complete amino acid sequencing; solid-phase binding inhibition assays with Gla domain peptide fragments; Ca2+ binding measurements; 3D model construction Biochemistry Medium 9860851
2001 FXa acts as a mitogen for human mesangial cells via proteolytic activity, inducing calcium mobilization, JNK activation, tyrosine kinase signaling, and PDGF A/B chain upregulation through a protease-activated receptor (not EPR-1); PKC activation is partially involved. DNA synthesis assays; serine protease inhibitor (leupeptin); neutralizing anti-PDGF antibody; tyrosine kinase inhibitors (genistein, herbimycin A); PKC downregulation; RT-PCR for EPR-1 Journal of the American Society of Nephrology : JASN Medium 11316847
2017 The Gla domain of FX mediates PS-specific membrane binding; molecular dynamics simulations identified PS-specific binding sites in FX-GLA and showed convergent membrane-bound configuration across 14 independent simulations. Molecular dynamics simulations using highly mobile membrane mimetic (HMMM); conventional membrane simulations Journal of thrombosis and haemostasis : JTH Low 28782177
2021 Factor X binds exactly one PS molecule per Gla domain when PE is present in excess (stoichiometry ~1.05 PS per FX molecule), identifying a single truly PS-specific binding site per Gla domain while remaining membrane interactions are satisfied by PE. Surface plasmon resonance with Nanodiscs of defined phospholipid composition Journal of thrombosis and haemostasis : JTH Medium 34894064
2017 The C. canimorsus protease CcDPP7 (type 7 dipeptidyl peptidase, S46 serine protease family) inactivates human FX by N-terminal cleavage of both heavy and light chains, inhibiting thrombin generation and prolonging clotting times in vivo. Mutagenesis of Cc5 genes; protein purification; Edman degradation for N-terminal cleavage site; clotting assays; in vivo tail bleeding time in mice Journal of thrombosis and haemostasis : JTH High 28029716
2000 FX deficiency causes partial embryonic lethality (~1/3 of FX-/- embryos die ~E11.5-12.5) and fatal neonatal bleeding (90% die within 5 days from intraabdominal hemorrhage), establishing FX as essential for embryonic and postnatal hemostasis. Targeted gene replacement (knockout mice); genotyping of offspring; histological analysis Thrombosis and haemostasis High 10739370
2000 The murine FX promoter is TATA-less with two transcription start sites; NF-Y, HNF-4, and GATA-4 bind the proximal promoter and regulate FX expression, with NF-Y being most critical (ablation reduces activity to 10% of wild-type). DNase I footprinting; EMSA; transient transfection in HepG2 cells; promoter deletion analysis Thrombosis and haemostasis Medium 11154110
2015 The FX carboxyl-terminal region (downstream of K467) is not essential for secretion or procoagulant activity; deletion of up to 21 carboxyl-terminal residues does not affect secretion or amidolytic activity, in contrast to the homologous regions in FVII, FIX, and PC. Recombinant expression of progressively truncated FX variants in HEK293, HepG2, and BHK21 cells; ELISA; coagulant and amidolytic assays; chimeric FX-FVII constructs Journal of thrombosis and haemostasis : JTH Medium 26083275
2021 FXa promotes RPE epithelial-mesenchymal transition (EMT) and intraocular fibrosis via PAR1-dependent phospho-activation of p38 MAPK; TGF-β receptor signaling also contributes to FXa-induced fibrosis in vivo. FXa ELISA in vitreous; in vitro RPE cell EMT assays; in vivo mouse PVR model with FXa injection; Western blotting for p38, α-SMA; pharmacological inhibitors of FXa, thrombin, and TGF-βR Investigative ophthalmology & visual science Medium 34283209
2011 The Ad5-FX-HSPG pathway mediating liver transduction in rodents is conserved in non-human primates (Microcebus murinus); FX-binding-ablated Ad5 vectors target the spleen rather than the liver in these animals. Quantitative viral genome and gene transfer measurement in non-human primates after IV administration of wild-type vs. FX-binding-ablated Ad5 Gene therapy Medium 21677690
1986 Human FX is synthesized as a single-chain precursor that is proteolytically cleaved to a dimeric form; it contains a leader (prepro) sequence; the 5'-coding region is 60% homologous to factor IX and 40% homologous to prothrombin, consistent with gene duplication. cDNA cloning and sequencing from human liver library using synthetic oligonucleotide probes Gene Medium 3011603
2024 Substitution of phenylalanine 174 (F174) in FXa with alanine, isoleucine, or serine reduces binding affinity for direct FXa inhibitors (apixaban, rivaroxaban, edoxaban) and also partially reduces inhibition by TFPI, enabling these variants to restore thrombin generation in inhibitor-containing plasma. Site-directed mutagenesis; stable expression in HEK293; thrombin generation assays; molecular dynamics simulations for binding affinity; testing in patient plasma Journal of thrombosis and haemostasis : JTH Medium 38729577
2018 FX recruits macrophages and promotes M2 polarization in GBM by binding ERK1/2 (inhibiting p-ERK1/2 in tumor cells) and increasing p-ERK1/2 and p-AKT phosphorylation in macrophages; FX expression is regulated by miR-338-3p and lncRNA CASC2c. Chemotaxis assays; macrophage polarization assays; co-immunoprecipitation/binding for ERK1/2; ERK/AKT phosphorylation western blots; miRNA overexpression/knockdown Frontiers in immunology Low 30034397
2025 Glioblastoma cells express and secrete catalytically active FX (including a C-terminal truncated alternatively spliced form); secreted FX is active in promoting thrombin generation and is upregulated by LPS stimulation or oxygen/glucose starvation. RT-PCR and Sanger/amplicon sequencing of F10 isoforms; Western blotting; chromogenic FX activity assay; thrombin generation assay on conditioned medium Biomedicines Medium 40149552

Source papers

Stage 0 corpus · 39 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2019 Myeloid cell-synthesized coagulation factor X dampens antitumor immunity. Science immunology 128 31541031
2013 Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement. Nature medicine 127 23524342
2012 Coagulation factor X activates innate immunity to human species C adenovirus. Science (New York, N.Y.) 126 23019612
2000 Blood coagulation factor X deficiency causes partial embryonic lethality and fatal neonatal bleeding in mice. Thrombosis and haemostasis 124 10739370
1997 Activation of blood coagulation factor X by arginine-specific cysteine proteinases (gingipain-Rs) from Porphyromonas gingivalis. The Journal of biological chemistry 93 9188512
1998 Coagulation factor X-binding protein from Deinagkistrodon acutus venom is a Gla domain-binding protein. Biochemistry 68 9860851
2010 Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X. PLoS pathogens 65 20949078
2018 Coagulation Factor X Regulated by CASC2c Recruited Macrophages and Induced M2 Polarization in Glioblastoma Multiforme. Frontiers in immunology 48 30034397
2021 Blood coagulation factor X: molecular biology, inherited disease, and engineered therapeutics. Journal of thrombosis and thrombolysis 39 33886037
2014 Polyphenol compounds belonging to flavonoids inhibit activity of coagulation factor X. International journal of biological macromolecules 38 24444877
2011 Coagulation factor X mediates adenovirus type 5 liver gene transfer in non-human primates (Microcebus murinus). Gene therapy 37 21677690
2017 Lipid specificity of the membrane binding domain of coagulation factor X. Journal of thrombosis and haemostasis : JTH 33 28782177
1995 An activator of blood coagulation factor X from the venom of Bungarus fasciatus. Toxicon : official journal of the International Society on Toxinology 27 8599179
1986 Isolation and characterization of human blood-coagulation factor X cDNA. Gene 25 3011603
2021 Autoimmune Coagulation Factor X Deficiency as a Rare Acquired Hemorrhagic Disorder: A Literature Review. Thrombosis and haemostasis 18 33930902
2015 The carboxyl-terminal region is NOT essential for secreted and functional levels of coagulation factor X. Journal of thrombosis and haemostasis : JTH 17 26083275
2001 Activated coagulation factor X: a novel mitogenic stimulus for human mesangial cells. Journal of the American Society of Nephrology : JASN 15 11316847
2024 Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer. Cancer cell 13 39303726
2019 An Inhibitor of Activated Blood Coagulation Factor X Shows Anti-Endothelial Senescence and Anti-Atherosclerotic Effects. Journal of vascular research 13 31266015
2000 Characterization of the murine coagulation factor X promoter. Thrombosis and haemostasis 13 11154110
2021 Activated Blood Coagulation Factor X (FXa) Contributes to the Development of Traumatic PVR Through Promoting RPE Epithelial-Mesenchymal Transition. Investigative ophthalmology & visual science 12 34283209
2016 Coagulation profile, gene expression and bioinformatics characterization of coagulation factor X of striped murrel Channa striatus. Fish & shellfish immunology 12 27235370
1998 Cloning and recombinant expression of mouse coagulation factor X. Thrombosis research 12 9783672
2021 Associations of coagulation factor X and XI with incident acute coronary syndrome and stroke: A nested case-control study. Journal of thrombosis and haemostasis : JTH 11 34351069
2017 Inactivation of human coagulation factor X by a protease of the pathogen Capnocytophaga canimorsus. Journal of thrombosis and haemostasis : JTH 11 28029716
2002 Blood coagulation factor X (FX) in human seminal plasma. Archives of andrology 10 12137590
2018 Blood Coagulation Factor X Exerts Differential Effects on Adenovirus Entry into Human Lymphocytes. Viruses 8 29301346
2021 Stoichiometric analysis reveals a unique phosphatidylserine binding site in coagulation factor X. Journal of thrombosis and haemostasis : JTH 6 34894064
2018 The carboxyl-terminal region of human coagulation factor X as a natural linker for fusion strategies. Thrombosis research 6 30453126
1993 Coagulation factor X inhibitor from hundred-pace snake (Deinagkistrodon acutus) venom. Toxicon : official journal of the International Society on Toxinology 6 8310445
2019 Co-localization of Coagulation Factor X and its Inhibitory System, PZ/ZPI, in Human Endometrial Cancer Tissue. In vivo (Athens, Greece) 5 31028196
2000 Cloning and characterization of the murine coagulation factor X gene. Thrombosis and haemostasis 5 10823271
2024 Kinetics and regulation of coagulation factor X activation by intrinsic tenase on phospholipid membranes. Journal of theoretical biology 4 38336240
2022 Human coagulation factor X and CD5 antigen-like are potential new members of the zonulin family proteins. Biochemical and biophysical research communications 3 36446155
2021 Identification of a modified coagulation factor X with enhanced activation properties as potential hemostatic agent. Blood cells, molecules & diseases 3 33962291
2024 Minimally modified human blood coagulation factor X to bypass direct factor Xa inhibitors. Journal of thrombosis and haemostasis : JTH 2 38729577
2025 Glioblastoma Cells Express and Secrete Alternatively Spliced Transcripts of Coagulation Factor X. Biomedicines 1 40149552
2025 A mathematical model for activated platelet-dependent activation of coagulation factor X by factor IXa. Computers in biology and medicine 0 40288296
2025 Selective targeting of coagulation factor X Gla domain by negatively charged gold nanoparticles: a novel method for controlled antithrombotic therapy. Materials today. Bio 0 41111485

Missed literature

Know a paper Affinage missed for F10? Flag it for the maintainers and the community.

No submissions yet.